Jasper Therapeutics holds special shareholder meeting
JSPR•Jasper Therapeutics shareholders approved a charter amendment authorizing the board to implement a 1-for-15 to 1-for-35 reverse stock split by Dec. 31, 2026, at its discretion. They also approved increasing authorized common shares to 675 million from 490 million and allowing adjournment to solicit additional proxies if needed.
1. Shareholders approve measures
Jasper Therapeutics held a special shareholder meeting on September 30, 2026. Shareholders backed a charter amendment authorizing the board to implement a reverse stock split by Dec. 31, 2026, at a ratio within a 1-for-15 to 1-for-35 range; execution remains at the board’s discretion.
2. Share authorization and adjournment
Investors adopted an amendment to raise authorized common shares to 675 million from 490 million, subject to board action. They also adopted a measure allowing adjournment to solicit additional proxies, if needed.
